This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biotech Stock Mailbag: Curagen, Nuvelo

The Biotech Mailbag is open for business. An email from Ruth G. about melanoma drugs kicks us off.

"Check out CRO-011 from Curagen (CRGN). I work in a medical lab (not Curagen's) and I think it's the best of the lot," she writes.

CRO-011 is an "armed antibody," which uses a monoclonal antibody to specifically target and kill cancer cells using a potent chemotherapy payload. Companies like ImmunoGen (IMGN) and Seattle Genetics (SGEN) are developing their own versions of armed antibody cancer drugs. In fact, Curagen's CRO-011 relies on the linker technology from Seattle Genetics to connect the antibody to the chemo payload.

CRO-11 is in the midst of a phase II study in heavily pre-treated melanoma patients, with results expected later this quarter. Initial data from a dose-ranging portion of this study were presented at the American Society of Clinical Oncology annual meeting last June.

Those data didn't exactly set the ASCO meeting on fire. Of the 13 patients treated with a 1.34 mg/kg dose of CRO-011, there was one patient with a partial response and six with stable disease. Six patients were evaluable at the 1.88 mg/kg dose used in the ongoing phase II study, with one unconfirmed partial response and three stable disease.

To be fair, these are tough patients to treat because they have advanced disease, so any activity is encouraging. But then, melanoma is one of the most difficult, if not the most difficult, cancer types for which to develop new drugs. The list of melanoma drug failures is long and grows every year.

At around 80 cents a share and a micro-market cap of $43 million, Curagen is a pure speculative play on CRO-011. To hammer home that point, consider that Curagen has a negative enterprise value of $15 million, which means investors essentially value the company's technology at zero. Results from the phase II study, due before year end, should shed more light on CRO-011's prospects.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CELG $118.68 0.00%
PFE $34.53 0.00%
SNTA $2.30 0.00%
AAPL $123.25 0.00%
FB $83.30 0.00%

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs